A.M.S. Mayer, Ph.D.
Professor of Pharmacology

Department of Pharmacology
Chicago College of Osteopathic Medicine
Midwestern University
555 31st Street
Downers Grove, IL 60515

 

Phone: (630) 515-6951
Fax: (630) 515-6295
E-mail: amayer@midwestern.edu

Home General Public Preclinical Pipeline Clinical Pipeline Seminars Meetings/Courses Links

MARINE PHARMACEUTICALS:
THE CLINICAL PIPELINE

As of February 2014, shown below are the marine-derived compounds which have been FDA-approved or are in Phase III, II or I of drug development (See http://clinicaltrials.gov/) and are part of the global marine pharmaceutical clinical pipeline. Since A.M.S. Mayer, K.B. Glaser, C. Cuevas, R.S. Jacobs, W. Kem, R.D. Little, J. M McIntosh, D.J. Newman, B.C. Potts and D. E. Shuster, Trends in Pharmacological Sciences, 31:255-265, 2010 ). Please note: Clinical trials with Soblidotin (TZT 1027), Tasidotin, Synthadotin (ILX-651), Hemiasterilin (E7974), Elisidepsin (Irvalec®), Pseudopterosin, and Plinabulin (NPI 2358) have been completed or discontinued (See http://clinicaltrials.gov/). Nereus Pharmaceuticals, Inc. (http://www.nereuspharm.com/ has been sold and no longer has a presence on the web.

Clinical
Status
Compound
Name
Trademark Marine
Organisma
Chemical
Class
Molecular
Target
Clinical
Trialsb
Disease
Area
Company/
Institutionc
FDA-Approved Cytarabine
(Ara-C)
Cytosar-U® Sponge Nucleoside DNA polmerase 814 Cancer 1
Vidarabine
(Ara-A)
Vira-A® Sponge Nucleoside Viral DNA polymerase 0 Antiviral NA
Ziconotide Prialt® Cone snail Peptide N-Type Ca chanel 5 Pain 3
Eribulin Mesylate (E7389) Halaven® Sponge Macrolide Microtubules 62 Cancer 4
Omega-3-acid ethyl esters Lovaza® Fish Omega-3 fatty acids Trygliceride-synthesizing enzymes 124 Hypertriglyceridemia 5
Trabectedin
(ET-743)
(EU Registered only)
Yondelis® Tunicate Alkaloid Minor groove of DNA 42 Cancer 6
Brentuximab vedotin
(SGN-35)
Adcetris® Mollusk/
cyanobacterium
Antibody drug conjugate (MM auristatin E) CD30 & microtubules 35 Cancer 7
Phase III
Plitidepsin Aplidin® Tunicate Depsipeptide Rac1 & JNK activation 7 Cancer 6
Tetrodotoxin Tectin® Pufferfish Guanidinium alkaloid Soduim Channel 2 Pain 11
Phase II DMXBA
(GTS-21)
NA Worm Alkaloid α7 nicotinic acetylcholine receptor 4 Schizophrenia UCHSC
PM00104 Zalypsis® Mollusk Alkaloid DNA-binding 3 Cancer 6
PM01183 NA Tunicate Alkaloid Minor groove of DNA 4 Cancer 6
CDX-011 NA Mollusk/
cyanobacterium
Antibody drug conjugate (MM auristatin E) Glycoprotein NMB & microtubules 3 Cancer 9
Phase I Marizomib (Salinosporamide A; NPI-0052) NA Bacterium Beta-lactone-gamma lactam 20S proteasome 4 Cancer 8
PM060184 NA Sponge Polyketide Minor groove of DNA 1 Cancer 6
Bryostatin NA Bryozoan Macrolide
Iactone
Protein kinase C 38 Cancer 10
SGN-75   NA Mollusk/
cyanobacterium
Antibody drug conjugate (MM auristatin F) CD70 & microtubules 2 Cancer 7
ASG-5ME NA Mollusk/
cyanobacterium
Antibody drug conjugate (MM auristatin E) ASG-5 & microtubules 2 Cancer 7

Abbreviations: FDA: Food and Drug Administration, www.fda.gov; NA: not available; NCI: National Cancer Institute; UCHSC: University of Colorado Health Sciences Center

 

a The marine pharmaceutical pipeline consists of natural products, analogs or derivatives of compounds produced by this marine organism or a symbiont (e.g. cyanobacterium).

b Ongoing clinical/total trials as reported at http://www.clinicaltrials.gov/ in February 2014

c Company/Institution:

1 Bedford Laboratories: http://www.bedfordlabs.com/our_products/online_catalog/products/cytarabine.html/;

3Azurpharma: http://www.azurpharma.com/

4 Eisai Inc.:http://us.eisai.com/section.asp?ID=287;

5 GlaxoSmithKline: http://www.gsk.com/;

6Pharmamar: http://www.pharmamar.com/products-professionals.aspx;

7 Seattle Genetics: http://www.seattlegenetics.com/pipeline;

8 Triphase Accelerator Corporation. http://triphaseco.com/pipeline//;

9Celldex Therapeutics, Inc.: http://www.celldextherapeutics.com/;

10National Cancer Institute.: http://www.cancer.gov/;

11Wex Pharmaceuticals Inc..: http://www.wextech.ca/;


Copyright © 2005-2014 Midwestern University. Last Rev. 02/28/2014. Direct questions or comments to Site Coordinator